Radius Health (RDUS) PT Raised to $45 at Jefferies

Jefferies analyst Eun Yang boosted his price target on Buy-rated Radius Health (NASDAQ: RDUS) to $45.00 (from $26.00) after as successful Phase 4 for Abaloparatide-SC.

Yang commented, "Ph3 for ABL in osteoporosis hit all endpoints of study for regulatory approval & for potential advantages (vs. Forteo, $1.25B in 2013 sales). While ABL commercial potential can be debatable, we view current valuation implies below our ~31% increased peak estimate of $670M. Now with positive Ph3 asset, progress in potentially differentiated breast cancer product RAD1901 (initial Ph1b data in 2015) will likely provide further upside."

For an analyst ratings summary and ratings history on Radius Health click here. For more ratings news on Radius Health click here.

Shares of Radius Health closed at $37.45 yesterday.

You May Also Be Interested In

• Energy Fuels (UUUU) PT Raised to $29.25 at H.C. Wainwright
• Piper Sandler Double Downgrades Myriad Genetics (MYGN) to Underweight, 'Major Strategic Action Likely Needed'
• BofA Securities Downgrades Edison International (EIX) to Neutral, 'A once-in-a-generation reform opportunity falls short'